ArticlePediatric blood & cancer2026
Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia.
Article in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Prediction of avatrombopag-induced thrombocytosis in pediatric immune thrombocytopenia: an AI-based real-world study.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAvatrombopag, a second-generation thrombopoietin receptor agonist (TPO-RA), is approved for treatment of chronic immune thrombocytopenia (ITP) in adults and has been studied in a Phase 3 trial in pediatric ITP. The reported efficacy, oral administration, safety profile, and lack of dietary restrictions are appealing treatment characteristics for children. Data on real-world use in children are limited.
methodsThis multicenter cohort study included patients diagnosed with ITP at age < 21 years treated with avatrombopag. Clinical features were collected from electronic medical records. Overall platelet response was defined as platelet count ≥ 30 × 10
resultsA total of 58 pediatric patients were treated with avatrombopag. Median time from diagnosis to treatment initiation was 4.6 years, with a median of 3 (range 0-11) prior treatments. Overall platelet response was 89.3% with similar response in primary and secondary ITP. Most patients achieved a response on the initial dose. Response rates did not differ by age at treatment initiation. Median time to platelet response was 13.5 days. High-grade bleeding scores were lower after initiation of treatment. Most patients (62%) switched from another TPO-RA to avatrombopag. Response to prior TPO-RA was associated with higher likelihood of response to avatrombopag (OR 15.00, 95% CI 1.824-187.7, p = 0.017). Of 12 patients with no response to prior TPO-RA, 8 responded to avatrombopag. Adverse effects were rare.
conclusionsIn this real-world study, avatrombopag was highly effective at both improving platelet counts and reducing bleeding in children with ITP, even in patients with secondary ITP or who had failed other TPO-RAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.